FDA warns New Mexico eye bank over distributing eye tissue from two donors with sepsis.
What happened
FDA inspected the eye bank from February 23 to February 28, 2024. It found that two donors with documented sepsis or septic shock and multiple signs of infection in the hospital stay before death were determined eligible, and ocular tissue from both was distributed. FDA also found the eye bank’s procedures and sepsis algorithm did not include all clinical evidence of sepsis or severe signs, and it called the company’s March 20, 2024 response inadequate.
What FDA found
FDA found that two donors with documented sepsis or septic shock and systemic signs of infection were determined eligible, and ocular tissue from both was distributed.
21 CFR 1271.75(d)The eye bank’s donor screening, eligibility, and sepsis algorithm procedures did not include all clinical evidence and systemic responses to infection or severe signs such as unexplained low oxygen, high lactate, low urine output, altered mental status, and low blood pressure.
21 CFR 1271.47(a)
What FDA wants
FDA asks the eye bank to respond in writing within 15 working days with specific corrective steps, how it will prevent recurrence, and documentation showing correction, or explain any delay and give a completion timeframe.
Who should pay attention
- other eye banks and tissue banks
- hospitals and surgeons who implant ocular tissue
- donor screening and transplant safety teams
This is a summary. Read the original letter on fda.gov.